Skip to content

A multicenter, prospective clinical study on near-infrared fluorescence imaging of colorectal cancer liver metastases

A multicenter, prospective clinical study of near-infrared fluorescence imaging-guided precise laparoscopic hepatectomy for colorectal cancer liver metastases

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200058961
Enrollment
Unknown
Registered
2022-04-20
Start date
2022-05-01
Completion date
Unknown
Last updated
2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver metastasis from colorectal cancer

Interventions

Group A:Traditional liver resection
Group B:ICG fluorescence image-guided hepatectomy

Sponsors

The First Affiliated Hospital of University of Science and Technology of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Identify simultaneous or heterogeneous liver metastases in patients diagnosed with colorectal cancer; 2. Preoperative abdominal enhanced CT and Promethein (disodium gadolinium) MRI with typical liver metastases; 3. Liver metastases were evaluated as resectable (all metastases in the liver could be resected; The residual liver volume after resection is greater than 30% of the original volume); 4. Patients with ICG15-minute retention rate 18 years and <75 years, no gender restriction; 6. Tolerance to general anesthesia, ASA anesthesia grade 3 or below, no complications of serious heart, lung and brain diseases; 7. Agree to sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Allergic to indocyanine green or iodine; 2. The Investigator believes that the subject may not be able to complete the study or comply with the requirements of the study (for administrative reasons or otherwise).

Design outcomes

Primary

MeasureTime frame
Number of liver lesions detected;1-year recurrence rate;

Secondary

MeasureTime frame
3-year relapse and survival rate;Postoperative complication rate;

Countries

China

Contacts

Public ContactLiu Lianxin
472373187@qq.com+86 18096656677

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026